Peginterferon Alfa-2a for AIDS-associated kaposi sarcoma: Experience with 10 patients
Authors / Editors
Research Areas
No matching items found.
Publication Details
Output type: Journal article
Author list: Rokx C., Van Der Ende M., Verbon A., Rijnders B.
Publisher: Oxford University Press
Publication year: 2013
Journal: Clinical Infectious Diseases (1058-4838)
Volume number: 57
Issue number: 10
Start page: 1497
End page: 1499
Number of pages: 3
ISSN: 1058-4838
eISSN: 1537-6591
URL: http://api.elsevier.com/content/abstract/scopus_id:84887979829
Unpaywall Data
Open access status: bronze
Full text URL: https://academic.oup.com/cid/article-pdf/57/10/1497/813903/cit517.pdf
Abstract
In this observational cohort study, 10 patients with extensive or treatment-refractory AIDS-associated Kaposi sarcoma were treated with peginterferon alfa-2a. Tumor responses were observed in 9 patients with a median progression-free survival of 645 days. Peginterferon alfa-2a could be an effective therapy for extensive or treatment-resistant Kaposi sarcoma. © The Author 2013.
Keywords
Highly active antire-troviral therapy, HIV/AIDS, Kaposi sarcoma, Peginterferon alfa-2a, Treatment effectiveness
Documents
No matching items found.
